Cover Image
լdi

神經毒氣、農藥中毒:開發中產品分析

Nerve Gas & Pestiside Poisioning - Pipeline Review, H2 2014

X Global Markets Direct ӫ~sX 269900
X eT ^ 45 Pages
q槹YɥI
Back to Top
神經毒氣、農藥中毒:開發中產品分析 Nerve Gas & Pestiside Poisioning - Pipeline Review, H2 2014
X: 2014~1025 eT: ^ 45 Pages
²

本報告提供對神經毒氣、農藥中毒的治療藥的開發情形調查分析、開發中產品的概要、臨床實驗各階段的產品概要、主要企業簡介、藥物簡介、開發中產品的最新趨勢、最新消息和新聞稿等,為您概述為以下內容。

目錄

簡介

神經毒氣、農藥中毒概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

正在開發的治療藥:各企業

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:各大學/實驗室

治療藥的開發企業

  • Baxter International Inc.
  • PharmAthene, Inc.
  • Protalix BioTherapeutics, Inc.
  • MicroDose Therapeutx, Inc.

治療藥的評估

  • 是單獨療法的情況
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • MDT-010
  • PRX-105
  • 血漿來源Butyrylcholinesterase
  • 第2代 Protexia
  • 神經毒氣、農藥中毒的肽

開發中產品的最新趨勢

暫停中的企劃

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

eiP̷sҮtCԲӱpлPڭpôC

ؿ
Product Code: GMDHC5645IDB

Summary

Global Markets Direct's, 'Nerve Gas & Pestiside Poisioning - Pipeline Review, H2 2014', provides an overview of the Nerve Gas & Pestiside Poisioning's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Nerve Gas & Pestiside Poisioning, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nerve Gas & Pestiside Poisioning and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Nerve Gas & Pestiside Poisioning
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Nerve Gas & Pestiside Poisioning and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Nerve Gas & Pestiside Poisioning products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Nerve Gas & Pestiside Poisioning pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Nerve Gas & Pestiside Poisioning
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Nerve Gas & Pestiside Poisioning pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Nerve Gas & Pestiside Poisioning Overview
  • Therapeutics Development
    • Pipeline Products for Nerve Gas & Pestiside Poisioning - Overview
    • Pipeline Products for Nerve Gas & Pestiside Poisioning - Comparative Analysis
  • Nerve Gas & Pestiside Poisioning - Therapeutics under Development by Companies
  • Nerve Gas & Pestiside Poisioning - Therapeutics under Investigation by Universities/Institutes
  • Nerve Gas & Pestiside Poisioning - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Nerve Gas & Pestiside Poisioning - Products under Development by Companies
  • Nerve Gas & Pestiside Poisioning - Products under Investigation by Universities/Institutes
  • Nerve Gas & Pestiside Poisioning - Companies Involved in Therapeutics Development
    • Baxter International Inc.
    • Teva Pharmaceutical Industries Limited
    • PharmAthene, Inc.
    • Protalix BioTherapeutics, Inc.
    • PlantForm Corporation
  • Nerve Gas & Pestiside Poisioning - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • atropine sulfate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PRX-105 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Plasma Derived Butyrylcholinesterase - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Second Generation Protexia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptides for Nerve Gas and Pestiside Poisioning - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Butyrylcholinesterase - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Nerve Gas & Pestiside Poisioning - Recent Pipeline Updates
  • Nerve Gas & Pestiside Poisioning - Dormant Projects
  • Nerve Gas & Pestiside Poisioning - Product Development Milestones
    • Featured News & Press Releases
      • Sep 08, 2014: PharmAthene and Nanotherapeutics Form Strategic Alliance to Advance Biodefense Programs
      • Jun 11, 2013: Therapure Biopharma Receives Subcontract Award From DynPort For Development Of Anti-Nerve Gas Agent
      • May 23, 2013: AIBioTech Receives Subcontract Award From DynPort For Continued Development And FDA Approval Of Nerve Agent Prophylactic
      • May 09, 2013: DynPort Vaccine Receives US Army Contract Worth $156.6m To Develop Nerve Gas Prophylactic
      • Apr 17, 2013: PharmAthene's Recombinant Butyrylcholinesterase Successfully Targets Nerve Agents In In-Vitro Study
      • Oct 24, 2011: Aeolus Announces NIH Counteract Grant Award To Develop AEOL 10150 As Treatment Against Nerve Agent Exposure
      • Jan 04, 2011: Protalix To Present PRX-105 Data At BARDA Industry Day
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Nerve Gas & Pestiside Poisioning, H2 2014
  • Number of Products under Development for Nerve Gas & Pestiside Poisioning - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Investigation by Universities/Institutes, H2 2014
  • Nerve Gas & Pestiside Poisioning - Pipeline by Baxter International Inc., H2 2014
  • Nerve Gas & Pestiside Poisioning - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014
  • Nerve Gas & Pestiside Poisioning - Pipeline by PharmAthene, Inc., H2 2014
  • Nerve Gas & Pestiside Poisioning - Pipeline by Protalix BioTherapeutics, Inc., H2 2014
  • Nerve Gas & Pestiside Poisioning - Pipeline by PlantForm Corporation, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Nerve Gas & Pestiside Poisioning Therapeutics - Recent Pipeline Updates, H2 2014
  • Nerve Gas & Pestiside Poisioning - Dormant Projects, H2 2014

List of Figures

  • Number of Products under Development for Nerve Gas & Pestiside Poisioning, H2 2014
  • Number of Products under Development for Nerve Gas & Pestiside Poisioning - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Target, H2 2014
  • Number of Products by Stage and Top 10 Target, H2 2014
  • Number of Products by Top 10 Mechanism of Action, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
  • Number of Products by Top 10 Route of Administration, H2 2014
  • Number of Products by Stage and Top 10 Route of Administration, H2 2014
  • Number of Products by Top 10 Molecule Type, H2 2014
  • Number of Products by Stage and Top 10 Molecule Type, H2 2014
Back to Top